We can’t show the full text here under this license. Use the link below to read it at the source.
Plasma biomarkers for early detection of alzheimer’s disease: a cross-sectional study in a Japanese cohort
Blood markers linked to early signs of Alzheimer’s disease in a Japanese group
AI simplified
Abstract
The area under the curves (AUCs) for predicting amyloid beta PET status were 0.946 for the ratio of to Aβ42.
- Plasma biomarkers Aβ42/40 and p-tau217, as well as their ratio, may serve as effective alternatives to amyloid PET imaging for diagnosing Alzheimer's disease.
- In cognitively normal participants, the AUCs for Aβ42/40 and p-tau217 were 0.968 and 0.958, respectively, indicating strong predictive capability.
- Cognitively impaired individuals showed AUCs of 0.919 for Aβ42/40 and 0.893 for p-tau217, reflecting the potential utility of these biomarkers in different stages of cognitive decline.
- Correlations between biomarker levels and cognitive performance were strong, particularly with logical memory scores, suggesting a relationship between these biomarkers and cognitive function.
- Aβ42/40 levels demonstrated a bimodal distribution among healthy controls and participants in the Alzheimer's continuum, highlighting its potential for early detection.
- P-tau217 levels increased linearly with disease progression, indicating its association with advancing Alzheimer's disease.
AI simplified
Key numbers
0.937
AUC for Aβ42/40
Area under the curve for Aβ42/40 predicting AD status.
0.926
AUC for
Area under the curve for predicting AD status.
0.946
AUC for /Aβ42 ratio
Area under the curve for the biomarker ratio predicting AD status.